Cargando…
A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting
BACKGROUND: Early detection of drug resistance is one of the priorities of tuberculosis (TB) control programs as drug resistance is increasing. New molecular assays are only accessible for a minority of the second line drugs and their availability in high endemic settings is also hampered by high co...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267144/ https://www.ncbi.nlm.nih.gov/pubmed/25108648 http://dx.doi.org/10.1186/1756-0500-7-512 |
_version_ | 1782349108100464640 |
---|---|
author | Wedajo, Wassihun Schön, Thomas Bedru, Ahmed Kiros, Teklu Hailu, Elena Mebrahtu, Tesfamariam Yamuah, Lawrence Ängeby, Kristian Werngren, Jim Onyebujoh, Philip Dagne, Kifle Aseffa, Abraham |
author_facet | Wedajo, Wassihun Schön, Thomas Bedru, Ahmed Kiros, Teklu Hailu, Elena Mebrahtu, Tesfamariam Yamuah, Lawrence Ängeby, Kristian Werngren, Jim Onyebujoh, Philip Dagne, Kifle Aseffa, Abraham |
author_sort | Wedajo, Wassihun |
collection | PubMed |
description | BACKGROUND: Early detection of drug resistance is one of the priorities of tuberculosis (TB) control programs as drug resistance is increasing. New molecular assays are only accessible for a minority of the second line drugs and their availability in high endemic settings is also hampered by high cost and logistic challenges. Therefore, we evaluated a previously developed method for drug susceptibility testing (DST) including both first- and second line anti-TB drugs for use in high endemic areas. RESULTS: Baseline mycobacterial isolates from 78 consecutive pulmonary TB patients from Addis Ababa, Ethiopia who were culture positive for Mycobacterium tuberculosis at the end of a two-month directly observed treatment short course (DOTS) were included. The isolates were simultaneously tested for isoniazid, rifampicin, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide and para-aminosalicylic acid susceptibility using the indirect proportion method adopted for 24-well agar plates containing Middlebrook 7H10 medium. Applying the 24-well plate assay, 43 (55.1%) isolates were resistant to one or more of the first line drugs tested (isoniazid, rifampicin and ethambutol). MDR-TB was identified in 20.5% of this selected group and there was a perfect correlation for rifampicin resistance with the results from the genotype MTBDRplus assay. All isolates were susceptible to aminoglycosides and fluoroquinolones in agreement with the genotype MTBDRsl assay. The only tested second line drug associated to resistance was ethionamide (14.1% resistant). The method was reproducible with stable results for internal controls (one multi-drug resistant (MDR) and one pan-susceptible strain (H37Rv) and DST results could be reported at two weeks. CONCLUSIONS: The 24-well plate method for simultaneous DST for first- and second line drugs was found to be reproducible and correlated well to molecular drug susceptibility tests. It is likely to be useful in high-endemic areas for surveillance as well as for the detection of second line drug resistance in targeted groups such as in those who fail empirical MDR treatment. |
format | Online Article Text |
id | pubmed-4267144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42671442014-12-17 A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting Wedajo, Wassihun Schön, Thomas Bedru, Ahmed Kiros, Teklu Hailu, Elena Mebrahtu, Tesfamariam Yamuah, Lawrence Ängeby, Kristian Werngren, Jim Onyebujoh, Philip Dagne, Kifle Aseffa, Abraham BMC Res Notes Research Article BACKGROUND: Early detection of drug resistance is one of the priorities of tuberculosis (TB) control programs as drug resistance is increasing. New molecular assays are only accessible for a minority of the second line drugs and their availability in high endemic settings is also hampered by high cost and logistic challenges. Therefore, we evaluated a previously developed method for drug susceptibility testing (DST) including both first- and second line anti-TB drugs for use in high endemic areas. RESULTS: Baseline mycobacterial isolates from 78 consecutive pulmonary TB patients from Addis Ababa, Ethiopia who were culture positive for Mycobacterium tuberculosis at the end of a two-month directly observed treatment short course (DOTS) were included. The isolates were simultaneously tested for isoniazid, rifampicin, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide and para-aminosalicylic acid susceptibility using the indirect proportion method adopted for 24-well agar plates containing Middlebrook 7H10 medium. Applying the 24-well plate assay, 43 (55.1%) isolates were resistant to one or more of the first line drugs tested (isoniazid, rifampicin and ethambutol). MDR-TB was identified in 20.5% of this selected group and there was a perfect correlation for rifampicin resistance with the results from the genotype MTBDRplus assay. All isolates were susceptible to aminoglycosides and fluoroquinolones in agreement with the genotype MTBDRsl assay. The only tested second line drug associated to resistance was ethionamide (14.1% resistant). The method was reproducible with stable results for internal controls (one multi-drug resistant (MDR) and one pan-susceptible strain (H37Rv) and DST results could be reported at two weeks. CONCLUSIONS: The 24-well plate method for simultaneous DST for first- and second line drugs was found to be reproducible and correlated well to molecular drug susceptibility tests. It is likely to be useful in high-endemic areas for surveillance as well as for the detection of second line drug resistance in targeted groups such as in those who fail empirical MDR treatment. BioMed Central 2014-08-10 /pmc/articles/PMC4267144/ /pubmed/25108648 http://dx.doi.org/10.1186/1756-0500-7-512 Text en © Wedajo et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wedajo, Wassihun Schön, Thomas Bedru, Ahmed Kiros, Teklu Hailu, Elena Mebrahtu, Tesfamariam Yamuah, Lawrence Ängeby, Kristian Werngren, Jim Onyebujoh, Philip Dagne, Kifle Aseffa, Abraham A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting |
title | A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting |
title_full | A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting |
title_fullStr | A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting |
title_full_unstemmed | A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting |
title_short | A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting |
title_sort | 24-well plate assay for simultaneous testing of first and second line drugs against mycobacterium tuberculosis in a high endemic setting |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267144/ https://www.ncbi.nlm.nih.gov/pubmed/25108648 http://dx.doi.org/10.1186/1756-0500-7-512 |
work_keys_str_mv | AT wedajowassihun a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT schonthomas a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT bedruahmed a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT kirosteklu a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT hailuelena a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT mebrahtutesfamariam a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT yamuahlawrence a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT angebykristian a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT werngrenjim a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT onyebujohphilip a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT dagnekifle a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT aseffaabraham a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT wedajowassihun 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT schonthomas 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT bedruahmed 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT kirosteklu 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT hailuelena 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT mebrahtutesfamariam 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT yamuahlawrence 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT angebykristian 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT werngrenjim 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT onyebujohphilip 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT dagnekifle 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting AT aseffaabraham 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting |